Clinical characteristics and long-term outcomes in SLE–myositis overlap syndrome: a controlled retrospective cohort study

Clicks: 13
ID: 327127
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #287 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Systemic lupus erythematosus (SLE) with concurrent inflammatory myositis (IIM) has a distinct clinical phenotype, yet its impact on long-term outcomes has been poorly defined. We aimed to determine the risk of mortality, malignancy, and severe renal disease in a large SLE cohort stratified by the presence of myositis. METHODS: We conducted a retrospective analysis of prospectively maintained, single-center cohort of 855 SLE patients followed between 1978 and 2024. Patients were stratified into two groups: SLE without myositis (n = 819) and SLE-myositis overlap (n = 36). Demographic, clinical, serological, and long-term outcome data were compared. Survival was analyzed using the Kaplan-Meier method and multivariable using cox proportional hazards regression. The study was an audit, not requiring formal hospital ethics approval or individual consent, due to the observational retrospective nature of the study using de-identified data-no individualized or identifiable data are presented in this study. RESULTS: Myositis was identified in 4.2% (36/855) of the SLE cohort. The SLE-myositis overlap group was characterized by a higher proportion of patients of Afro-Caribbean ethnicity (38.9% vs. 16.8%; p < 0.001) a greater frequency of interstitial lung disease (ILD) (13.8% vs. 1.2%; p < 0.001) and higher rates of anti-RNP positivity (61.1% vs. 20.1%; p < 0.001). All-cause mortality over a median follow-up of 22.4 years was over two-fold higher in the SLE-myositis group (30.5% vs. 14%; log-rank p < 0.001). Multivariable Cox regression confirmed that the presence of myositis was an independent predictor of mortality. ILD (HR 5.5, 95% CI 3.61-9.6; p = 0.004) and malignancy (HR 3.1, 95% CI 2.9-11.6; p < 0.001) were also independently associated with increased mortality. CONCLUSION: SLE-myositis overlap syndrome represents a clinically important subgroup characterized by a predominance of non-Caucasian patients and a higher burden of extra-renal disease.The presence of myositis is an important prognostic marker associated with increased long-term mortality in patients with SLE.
Reference Key
openalex_W7204779494 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors G. Sandal Uzun, David Isenberg
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag452
URL
https://doi.org/10.1093/rheumatology/keag452
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.